Giants of Cancer Care® Program Inductees

Breast Cancer

Lisa A. Carey, MD, ScM, FASCO

University of North Carolina at Chapel Hill

Carey's work is devoted to the understanding and characterization of molecular subtypes of breast cancer to further prevention and treatment advances.
Through collaboration with Charles M. Perou, PhD, and Robert C. Millikan, PhD, Carey discovered that young African American women are at a higher risk of developing the poor-prognosis basal-like breast cancer subtype.
Carey is a global expert in triple-negative breast cancer, having led the first trial evaluating a new treatment regimen in this patient population.
She led a National Cancer Institute (NCI)–sponsored trial in HER2-positive breast cancer that illustrated that tumor characteristics, including immune cell activation and subtype, were critical to outcomes with dual HER2-targeted therapy.
Carey is a member of the NCI Breast Cancer Steering Committee, cochair of the NCI-sponsored Alliance Breast Committee, cochair of the Translational Breast Cancer Research Consortium Steering Committee, and member of the board of directors of the American Society of Clinical Oncology.

Home

)

SUPPORTED BY